Literature DB >> 27628319

Expression of ADAM10, Fas, FasL and Soluble FasL in Patients with Oral Squamous Cell Carcinoma (OSCC) and their Association with Clinical-Pathological Parameters.

José Sergio Zepeda-Nuño1, Celia Guerrero-Velázquez2, Susana Del Toro-Arreola3, Natali Vega-Magaña3, Julián Ángeles-Sánchez4, Jesse Haramati5, Ana L Pereira-Suárez6, Miriam R Bueno-Topete7.   

Abstract

ADAM10 has been implicated in the progression of various solid tumors. ADAM10 regulates the cleavage of the FasL ectodomain from the plasma membrane of different cell types, generating the soluble FasL fragment (sFasL). Currently, there are few studies in oral squamous cell carcinoma (OSCC) that correlate levels of ADAM10 and FasL in the tumor microenvironment with clinical parameters of the disease. To determine the expression of ADAM10, Fas, FasL and sFasL in patients with OSCC and its association with TNM stage. Twenty-five patients with OSCC and 25 healthy controls were included. Biopsies of tumor tissue from patients with OSCC and buccal mucosa in controls were obtained. ADAM10, Fas, and FasL were analyzed by Western blotting. sFasL was quantified by ELISA. ADAM10 and Fas decreased significantly in OSCC compared with controls. Relatedly, within the OSCC group, Fas and ADAM10 decreased in accordance with tumor disease stage; in stages I/II, as well as in tumors of smaller diameter (T1-T2), ADAM10 showed higher levels when compared to patients with T3-T4 tumors and in stage III-IV. FasL in the tumor microenvironment and serum FasL showed no significant differences between both groups. Levels of complete FasL and cleaved FasL were positively correlated in controls; this correlation is preserved in patients with tumors in early stages (I-II), but is lost in later stage (III-IV). The dysregulation of ADAM10, Fas and FasL could be useful indicators of the progression and severity of OSCC.

Entities:  

Keywords:  ADAM10; Fas; FasL; Oral cancer; sFasL

Mesh:

Substances:

Year:  2016        PMID: 27628319     DOI: 10.1007/s12253-016-0102-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  32 in total

1.  ADAM 10 is over expressed in oral squamous cell carcinoma and contributes to invasive behaviour through a functional association with αvβ6 integrin.

Authors:  Adam V Jones; Daniel W Lambert; Paul M Speight; Simon A Whawell
Journal:  FEBS Lett       Date:  2013-09-18       Impact factor: 4.124

2.  Hypoxia stimulates release of the soluble form of fas ligand that inhibits endothelial cell apoptosis.

Authors:  M Mogi; K Fukuo; J Yang; T Suhara; T Ogihara
Journal:  Lab Invest       Date:  2001-02       Impact factor: 5.662

3.  The disintegrin and metalloproteinase ADAM10 mediates a canonical Notch-dependent regulation of IL-6 through Dll4 in human endothelial cells.

Authors:  Angélique Pabois; Julie Devallière; Thibaut Quillard; Flora Coulon; Nathalie Gérard; Christian Laboisse; Claire Toquet; Béatrice Charreau
Journal:  Biochem Pharmacol       Date:  2014-08-15       Impact factor: 5.858

Review 4.  ADAMs in cancer cell proliferation and progression.

Authors:  Satsuki Mochizuki; Yasunori Okada
Journal:  Cancer Sci       Date:  2007-03-09       Impact factor: 6.716

Review 5.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

Review 6.  Induction of tolerance using Fas ligand: a double-edged immunomodulator.

Authors:  Nadir Askenasy; Esma S Yolcu; Isaac Yaniv; Haval Shirwan
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

7.  Effects of FasL expression in oral squamous cell cancer.

Authors:  Li Fang; Lin Sun; Fang-Fang Hu; Qiao-Er Chen
Journal:  Asian Pac J Cancer Prev       Date:  2013

8.  Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin.

Authors:  Felix Scholz; Alexander Schulte; Frederic Adamski; Christian Hundhausen; Jens Mittag; Agatha Schwarz; Marie-Luise Kruse; Ehrhardt Proksch; Andreas Ludwig
Journal:  J Invest Dermatol       Date:  2007-03-15       Impact factor: 8.551

9.  The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10.

Authors:  Soeren Abel; Christian Hundhausen; Rolf Mentlein; Alexander Schulte; Theo A Berkhout; Neil Broadway; Dieter Hartmann; Radek Sedlacek; Sebastian Dietrich; Barbara Muetze; Bjoern Schuster; Karl-Josef Kallen; Paul Saftig; Stefan Rose-John; Andreas Ludwig
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

10.  Fas receptor (CD95) & Fas ligand (CD178) expression in patients with tobacco-related intraoral squamous cell carcinoma.

Authors:  Satya N Das; Pratima Khare; Manoj K Singh; Suresh C Sharma
Journal:  Indian J Med Res       Date:  2011-07       Impact factor: 2.375

View more
  2 in total

1.  Serum Proteomics in Patients with Head and Neck Cancer: Peripheral Blood Immune Response to Treatment.

Authors:  Thorsteinn Astradsson; Felix Sellberg; Ylva Tiblom Ehrsson; Karl Sandström; Göran Laurell
Journal:  Int J Mol Sci       Date:  2022-06-04       Impact factor: 6.208

2.  Overexpression of A disintegrin and metalloprotease 10 promotes tumor proliferation, migration and poor prognosis in hypopharyngeal squamous cell carcinoma.

Authors:  Chuanjin Ding; Qicheng Zhang; Yan Chen; Xiaobo Zhang; Pei Wu; Zhenxin Zhang
Journal:  Oncol Rep       Date:  2017-06-27       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.